Related Experiment Video
Updated: Oct 24, 2025

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
Published on: November 10, 2023
Neurological comorbidities and COVID-19-related case fatality: A cohort study
Alberto Romagnolo1, Gabriele Imbalzano1, Carlo Alberto Artusi1
1Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy; SC Neurologia 2U, AOU Città della Salute e della Scienza, Turin, Italy.
Insights
Pre-existing neurological conditions, especially neurodegenerative diseases, significantly increase the risk of death from Coronavirus disease-2019 (COVID-19). These findings highlight the need for prioritized screening, care, and vaccination for neurological patients.
Area of Science:
- Neurology
- Infectious Diseases
- Public Health
Background:
- Neurological involvement is a known complication of Coronavirus disease-2019 (COVID-19).
- The impact of pre-existing neurological conditions on COVID-19 mortality remains under investigation.
- This study examines the case fatality rate (CFR) in COVID-19 patients with prior neurological diagnoses.
Purpose of the Study:
- To assess the association between pre-existing neurological diseases and COVID-19 related mortality.
- To compare the CFR and survival outcomes in COVID-19 patients with and without neurological comorbidities.
Main Methods:
- Retrospective cohort study of 332 COVID-19 patients admitted between March-April 2020.
- Multivariate regression analysis to determine the association between neurological diseases and mortality.
- Propensity score matching (1:1) to compare CFR and survival curves between neurological and non-neurological patient groups.
Main Results:
- Patients with pre-existing neurological disease (22.6%) had a significantly increased risk of COVID-19 mortality (OR: 2.559, p < 0.017).
- The overall CFR was double in patients with neurological conditions (48.0% vs. 24.0%, p = 0.002).
- Neurodegenerative diseases showed a significantly higher CFR (73.9% vs. 39.1%, p = 0.017), while cerebrovascular diseases did not reach statistical significance.
Conclusions:
- Pre-existing neurological comorbidities, particularly neurodegenerative diseases, substantially increase COVID-19 case fatality.
- These findings underscore the critical need for prioritized screening, healthcare access, and vaccination for individuals with neurological conditions.
Background:
Neurological involvement in Coronavirus disease-2019 (COVID-19) is widely recognized. However, the role of pre-existing neurological comorbidities in modulating COVID-19-related mortality still remains unclear. This cohort study evaluates the COVID-19-related case fatality rate (CFR) of patients with pre-existing neurological diseases.
Methods:
We retrospectively evaluated all patients consecutively admitted to our hospital with a diagnosis of COVID-19 between March and April 2020. We used a multivariate regression analysis to estimate the association between pre-existing neurological diseases and COVID-19-related mortality. Then, we compared the CFR and survival curves of two cohorts (patients suffering vs. those not suffering from pre-existing neurological disease), matched trough the propensity score (PS). Age and other comorbidities were considered for PS calculation. We applied a 1:1 matching for the entire neurological cohort and, separately, for cerebrovascular, neurodegenerative, and other neurological diseases.
Results:
Among 332 patients, 75 (22.6%) were affected by pre-existing neurological disease (n = 29 cerebrovascular, n = 26 neurodegenerative, n = 20 others). From the multivariate regression analysis, they resulted with a significant increase of COVID-19-related mortality (OR:2.559; 95%CI 1.181-5.545; p < 0.017). From the cohort analysis, CFR resulted 2-fold higher in patients with neurological disease (48.0% vs. 24.0%; p = 0.002). CFR was significantly higher in patients with neurodegenerative diseases compared to matched individuals (73.9% vs. 39.1%; p = 0.017), while CFR increase in patients with cerebrovascular diseases did not reach statistical significance (48.3% vs. 41.4%; p = 0.597).
Conclusions:
Pre-existing neurological comorbidities, in particular neurodegenerative diseases, increase significantly COVID-19-related case fatality, indicating a clear priority for viral screening, access to care facilities and vaccination in these populations.
More Related Videos
Related Concept Videos
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Bias in Epidemiological Studies
Prevalence and Incidence
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Acute Coronary Syndrome III: Diagnostic Studies
Causality in Epidemiology

